- Home
- ADXN vs CVKD Comparison
ADXN vs CVKD Comparison
Compare ADXN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | CVKD |
|---|---|---|
| Founded | 2002 | 2022 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 20.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ADXN | CVKD |
|---|---|---|
| Price | $7.83 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 8.0K | ★ 76.2K |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,824.00 | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $6.76 |
| 52 Week High | $12.05 | $22.90 |
Technical Indicators
Market Signals| Indicator | ADXN | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 34.09 |
| Support Level | $7.01 | $7.43 |
| Resistance Level | $8.30 | $12.50 |
| Average True Range (ATR) | 0.43 | 1.10 |
| MACD | 0.02 | -0.23 |
| Stochastic Oscillator | 41.41 | 7.86 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.